<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Imatinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Imatinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Imatinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10756" href="/d/html/10756.html" rel="external">see "Imatinib: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12618" href="/d/html/12618.html" rel="external">see "Imatinib: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181929"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gleevec</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867176"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Imatinib;</li>
<li>APO-Imatinib;</li>
<li>Gleevec;</li>
<li>JAMP-Imatinib;</li>
<li>MINT-Imatinib;</li>
<li>NAT-Imatinib;</li>
<li>PMS-Imatinib [DSC];</li>
<li>TEVA-Imatinib</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F181958"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F181934"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Imatinib is associated with a moderate or high emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49c961bb-ce39-4a65-be68-00d42b082a27">Acute lymphoblastic leukemia, Philadelphia chromosome-positive, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, Philadelphia chromosome-positive, newly diagnosed (off-label population): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAAPH-2003 protocol:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Good early responders with corticosensitive and chemosensitive disease: Consolidation: <b>Oral:</b> 600 mg once daily starting on day 1 of consolidation (in combination with mitoxantrone, cytarabine, filgrastim, and triple intrathecal therapy) until day ~90 or until transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062730','lexi-content-ref-22960387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062730','lexi-content-ref-22960387'])">Ref</a></span>). Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:6em;">Poor early responders with corticoresistant and/or chemoresistant disease: Induction: <b>Oral: </b>800 mg/day for ~90 days or until transplant (in combination with vincristine, dexamethasone, and triple intrathecal therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17062730','lexi-content-ref-22960387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17062730','lexi-content-ref-22960387'])">Ref</a></span>). Refer to protocol for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAAPH-2005 protocol (imatinib in combination with low-intensity chemotherapy): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>Oral: </b>400 mg twice daily on days 1 to 28 (in combination with vincristine, dexamethasone, and filgrastim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25878120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25878120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 2:<b> Oral: </b>400 mg twice daily on days 1 to 14 (in combination with methotrexate, cytarabine, and growth factor support) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25878120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25878120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Depending on clinical response after cycle 2, patients could proceed to stem cell transplant. Refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25878120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25878120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Imatinib in combination with Hyper-CVAD: </i>
<b>Oral: </b>400 mg once daily on days 1 to 14 of cycles 1 to 8 of each intensive chemotherapy course, followed by maintenance therapy of 600 mg once daily for 13 months (in combination with vincristine and prednisone). Months 6 and 13 of maintenance therapy consisted of intensive therapy with Hyper-CVAD and imatinib 400 mg once daily on days 1 to 14 of each month; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14551133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14551133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>NILG protocol 09/00: </i>
<b>Note:</b> Imatinib is administered in combination with chemotherapy; refer to protocol for further information, including maintenance imatinib (if applicable) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20606084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20606084'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: <b>Oral: </b>600 mg once daily for 7 consecutive days, starting on day 15 of cycle 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20606084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20606084'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 2 to 8: <b>Oral: </b>600 mg once daily for 7 consecutive days, starting 3 days before chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20606084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20606084'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f95fcbc-09eb-46cb-bbe1-7e530e5ddfae">Acute lymphoblastic leukemia, Philadelphia chromosome-positive, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, Philadelphia chromosome-positive, relapsed/refractory:</b>
<b>Oral:</b> 600 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b72475cb-9e80-4fda-aa7d-8cb04d8c0d97">Aggressive systemic mastocytosis associated with eosinophilia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aggressive systemic mastocytosis associated with eosinophilia:</b>
<b>Oral:</b> Initiate at 100 mg once daily; if assessments demonstrate insufficient response, increase from 100 mg to 400 mg/day in the absence of adverse reactions; continue until disease progression or unacceptable toxicity. <b>Note: </b>Imatinib is not recommended for cutaneous mastocytosis, indolent systemic mastocytosis (smoldering systemic mastocytosis or isolated bone marrow mastocytosis), systemic mastocytosis with an associated clonal hematological non-mast cell lineage disease, mast cell leukemia, mast cell sarcoma, or extracutaneous mastocytoma; do not use imatinib for treatment of aggressive mastocytosis that contains the D816V mutation of c-kit.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e320f47a-5a9d-4f55-ad50-51d76e236218">Aggressive systemic mastocytosis without D816V c-Kit mutation or c-Kit mutation status unknown</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aggressive systemic mastocytosis without D816V c-kit mutation or c-kit mutation status unknown:</b>
<b>Oral:</b> 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="05a61b5b-65d7-4a70-bedf-167c3b210663">Chordoma, progressive, advanced, or metastatic expressing PDGFRB and/or PDGFB</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chordoma, progressive, advanced, or metastatic expressing PDGFRB and/or PDGFB (off-label use):</b>
<b>Oral:</b> 400 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22331945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22331945'])">Ref</a></span>) <b>or</b> (in patients with secondary resistance to imatinib and/or evidence of mTOR effector activation) 400 mg once daily (in combination with sirolimus) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22331945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22331945'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0632ab14-f4fd-49b6-93a6-477819ae42e6">Chronic myeloid leukemia, Philadelphia chromosome-positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia, Philadelphia chromosome-positive:</b>
<b> Note: </b>Treatment may be continued until disease progression or unacceptable toxicity. The optimal duration of therapy for chronic myeloid leukemia (CML) in complete remission is not yet determined.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32734668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32734668'])">Ref</a></span>): A British Society for Haematology guideline on the diagnosis and management of CML suggests that the first-generation tyrosine kinase inhibitor (TKI) imatinib is a reasonable option for initial therapy in chronic phase CML. A second-generation TKI may be considered as initial therapy for newly diagnosed chronic phase CML in patients with a high or intermediate EUTOS long-term survival (ELTS) or Sokal score; assess comorbidities and TKI toxicity profile to determine the appropriate TKI. An alternative TKI should be considered if treatment failure on first-line therapy occurs; the choice of second-line therapy should be guided by BCR-ABL mutational analysis as well as patient- and drug-specific characteristics. Patients with de novo accelerated phase CML should ideally be managed with a second-generation TKI. Some patients may be candidates for a treatment-free remission (TFR); specific criteria and monitoring parameters must be met in order to discontinue treatment; refer to guideline for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic phase: <b>Oral: </b>400 mg once daily; may be increased to 600 mg daily, if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6 to 12 months, or loss of previous hematologic or cytogenetic response. An increase to 800 mg daily has been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20008622','lexi-content-ref-24297946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20008622','lexi-content-ref-24297946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Accelerated phase or blast crisis: <b>Oral: </b>600 mg once daily; may be increased to 800 mg daily (400 mg twice daily), if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6 to 12 months, or loss of previous hematologic or cytogenetic response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0c4f5f2-1cf5-4415-852d-daa47ece32b5">Chronic myeloid leukemia, post-allogeneic hematopoietic cell transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia, post-allogeneic hematopoietic cell transplantation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylactic use to prevent relapse post-transplant:</i>
<b>Oral: </b>400 mg once daily starting after engraftment for 1 year post-transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17119111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17119111'])">Ref</a></span>) <b>or</b> 300 mg once daily starting on day +35 post SCT (increased to 400 mg once daily within 4 weeks) and continued until 12 months posttransplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17881635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17881635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapse post-transplant:</i>
<b>Oral: </b>Initial: 400 mg once daily; if inferior response after 3 months, dose may be increased to 600 to 800 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16234522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16234522'])">Ref</a></span>) <b>or</b> 400 to 600 mg daily (chronic phase) <b>or</b> 600 mg daily (blast or accelerated phase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15297408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15297408'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fece2e4-668f-4f0e-88c7-0bfc7eb69a42">Dermatofibrosarcoma protuberans</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatofibrosarcoma protuberans:</b>
<b>Oral:</b> 400 mg twice daily until disease progression or unacceptable toxicity. <b>Note: </b>Data from a pooled analysis of two phase 2 trials showed that response rates and time to progression did not differ between 400 mg/day and 800 mg/day doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20194851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20194851'])">Ref</a></span>); data from a systematic review also noted that there seemed to be no difference in outcomes between the 400 or 800 mg/day dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30601909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30601909'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0a34a64-3baf-48f6-9673-fa81ea38d70e">Desmoid tumors, locally advanced or progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desmoid tumors, locally advanced or progressive (off-label use):</b>
<b>Oral:</b> 300 mg twice daily (BSA ≥1.5 m<sup>2</sup>), 200 mg twice daily (BSA 1 to 1.49 m<sup>2</sup>), 100 mg twice daily (BSA &lt;1 m<sup>2</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20724445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20724445'])">Ref</a></span>) <b>or</b> 400 mg once daily; may escalate to 400 mg twice daily for progressive disease on 400 mg daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20622000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20622000'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d33cefa4-a759-4f8b-aef5-af5f750cd64f">Gastrointestinal stromal tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumor:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant treatment following complete resection:</i>
<b>Oral: </b>400 mg once daily; recommended treatment duration: 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19303137','lexi-content-ref-22453568']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19303137','lexi-content-ref-22453568'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Unresectable and/or metastatic malignant:</i>
<b>Oral:</b> 400 mg once daily; may be increased up to 800 mg daily (400 mg twice daily), if tolerated, for disease progression at 400 mg/day; continue until disease progression or unacceptable toxicity. <b>Note:</b> Significant improvement (progression-free survival, objective response rate) was demonstrated in patients with KIT exon 9 mutation with 800 mg (versus 400 mg), although overall survival (OS) was not impacted. The higher dose did not demonstrate a difference in time to progression or OS patients with Kit exon 11 mutation or wild-type status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16624552','lexi-content-ref-18955451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16624552','lexi-content-ref-18955451'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="825f8d64-14e3-4016-bfc6-4dcfd0b20840">Hypereosinophilic syndrome and/or chronic eosinophilic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypereosinophilic syndrome and/or chronic eosinophilic leukemia:</b>
<b>Oral:</b> 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1170f299-d841-4aaa-849b-4efc50291adf">Hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase:</b>
<b>Oral:</b> Initiate at 100 mg once daily; if assessments demonstrate insufficient response, increase from 100 mg to 400 mg/day in the absence of adverse reactions; continue until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98cca2f-a997-4e92-90cc-c3b0f51146f7">Melanoma, advanced or metastatic, c-Kit mutated tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, advanced or metastatic, c-kit mutated tumors (off-label use):</b>
<b>Oral:</b> 400 mg twice daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21642685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21642685'])">Ref</a></span>) <b>or</b> 400 mg once daily until disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23775962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23775962'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b8c2396-d785-405d-90d1-53719ee79871">Myelodysplastic/myeloproliferative disease with PDGFR gene rearrangements</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic/myeloproliferative disease with PDGFR gene rearrangements:</b>
<b>Oral:</b> 400 mg once daily until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult Drug Interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992095"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only 13% of an imatinib dose is eliminated in the urine (5% unchanged); therefore, dosage adjustments for kidney dysfunction are likely unnecessary. However, in a pharmacokinetic study, imatinib AUC was increased 1.5- to 2-fold in patients with mild (CrCl 40 to 59 mL/minute) and moderate (CrCl 20 to 39 mL/minute) kidney impairment, although doses were well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18235116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18235116'])">Ref</a></span>). Additionally, there may be an increased risk for worsening kidney function among patients with preexisting kidney impairment. Alternative treatments (eg, certain second-generation tyrosine kinase inhibitors less associated with kidney impairment) are preferred when clinically appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33275749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33275749'])">Ref</a></span>). Close monitoring of kidney function and avoiding use of other nephrotoxic drugs is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34894374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34894374'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥40 mL/minute: Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>). Subsequent dose adjustments (increase or decrease) should be based on the indication for use along with an assessment of tolerability/adverse effects and desired clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1','lexi-content-ref-EMA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1','lexi-content-ref-EMA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to &lt;40 mL/minute: Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>). Subsequent dose adjustments (increase or decrease) should be based on the indication for use along with an assessment of tolerability/adverse effects and desired clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1'])">Ref</a></span>). Doses up to 600 mg have been well tolerated in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18235116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18235116'])">Ref</a></span>). Alternatively, may initiate therapy with a reduced dose and gradually increase based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;20 mL/minute: Consider alternative agent due to limited clinical data and risk of imatinib-induced nephrotoxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">If necessary, no initial dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>); however, use with caution. Subsequent dose adjustments (increase or decrease) should be based on the indication for use along with an assessment of tolerability/adverse effects and desired clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1'])">Ref</a></span>). Alternatively, may initiate therapy with a reduced dose and gradually increase based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15883819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15883819'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>); however, use with caution due to limited clinical data (case reports) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19012999','lexi-content-ref-27403097','lexi-content-ref-16680756','lexi-content-ref-15883819','lexi-content-ref-22728491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19012999','lexi-content-ref-27403097','lexi-content-ref-16680756','lexi-content-ref-15883819','lexi-content-ref-22728491'])">Ref</a></span>). Subsequent dose adjustments (increase or decrease) should be based on the indication for use along with an assessment of tolerability/adverse effects and desired clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1'])">Ref</a></span>). Alternatively, may initiate therapy with a reduced dose and gradually increase based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis</b>
<b>:</b> Unlikely to be significantly dialyzed (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Consider alternative agent due to limited clinical data and risk of imatinib-induced nephrotoxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">If necessary, no initial dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>); however, use with caution due to limited clinical data and risk of imatinib-induced nephrotoxicity; may also consider use of an alternative agent. Subsequent dose adjustments (increase or decrease) should be based on the indication for use along with an assessment of tolerability/adverse effects and desired clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-EMA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-EMA.1'])">Ref</a></span>). Alternatively, may initiate therapy with a reduced dose and gradually increase based on tolerability and response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Nephrotoxicity during treatment:</i></b> Interrupt imatinib therapy and provide supportive care. When kidney function improves, may reinitiate imatinib at a full or reduced dose (depending on the severity of the kidney injury and how quickly it resolved) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33275749','lexi-content-ref-20564631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33275749','lexi-content-ref-20564631'])">Ref</a></span>). Alternatively, may consider switching to a second-generation tyrosine kinase inhibitor less associated with nephrotoxicity (eg, dasatinib, nilotinib) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27460678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27460678'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989310"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting hepatic impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer’s labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: Reduce dose by 25%.</p>
<p style="text-indent:-2em;margin-left:4em;">Krens 2019: No dose adjustment is needed.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Hepatotoxicity during treatment:</b> If elevations of bilirubin &gt;3 times ULN or transaminases &gt;5 times ULN occur, withhold treatment until bilirubin &lt;1.5 times ULN and transaminases &lt;2.5 times ULN. Resume treatment at a reduced dose as follows (<b>Note:</b> The decision to resume treatment should take into consideration the initial severity of hepatotoxicity):</p>
<p style="text-indent:-2em;margin-left:6em;">If current dose 400 mg daily, reduce dose to 300 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">If current dose 600 mg daily, reduce dose to 400 mg daily</p>
<p style="text-indent:-2em;margin-left:6em;">If current dose 800 mg daily, reduce dose to 600 mg daily</p></div>
<div class="block dot drugH1Div" id="F181959"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Hematologic toxicity:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Chronic phase CML (initial dose 400 mg daily in adults or 340 mg/m<sup>2</sup>/day in children); ASM, MDS/MPD, and HES/CEL (initial dose 400 mg daily); or GIST (initial dose 400 mg daily): If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L: Withhold until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L; resume treatment at original starting dose. For recurrent neutropenia and/or thrombocytopenia, withhold until recovery, and reinstitute treatment at a reduced dose as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥1 year and Adolescents: If initial dose 340 mg/m<sup>2</sup>/day, reduce dose to 260 mg/m<sup>2</sup>/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: If initial dose 400 mg daily, reduce dose to 300 mg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CML (accelerated phase or blast crisis): Adults (initial dose 600 mg daily): If ANC &lt;0.5 x 10<sup>9</sup>/L and/or platelets &lt;10 x 10<sup>9</sup>/L, establish whether cytopenia is related to leukemia (bone marrow aspirate or biopsy). If unrelated to leukemia, reduce dose to 400 mg daily. If cytopenia persists for an additional 2 weeks, further reduce dose to 300 mg daily. If cytopenia persists for 4 weeks and is still unrelated to leukemia, withhold treatment until ANC ≥1 x 10<sup>9</sup>/L and platelets ≥20 x 10<sup>9</sup>/L, then resume treatment at 300 mg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">ASM associated with eosinophilia and HES/CEL with FIP1L1-PDGFRα fusion kinase: Adults (starting dose 100 mg daily): If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L: Withhold until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L; resume treatment at previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">DFSP: Adults (initial dose 800 mg daily): If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L, withhold until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L; resume treatment at reduced dose of 600 mg daily. For recurrent neutropenia and/or thrombocytopenia, withhold until recovery, and reinstitute treatment with a further dose reduction to 400 mg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Ph+ ALL:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatrics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19805687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19805687'])">Ref</a></span>): Hematologic toxicity requiring dosage adjustments was not observed in the study. No major toxicities were observed with imatinib at 340 mg/m<sup>2</sup>/day in combination with intensive chemotherapy.</p>
<p style="text-indent:-2em;margin-left:6em;">Adults (initial dose 600 mg daily): If ANC &lt;0.5 x 10<sup>9</sup>/L and/or platelets &lt;10 x 10<sup>9</sup>/L, establish whether cytopenia is related to leukemia (bone marrow aspirate or biopsy). If unrelated to leukemia, reduce dose to 400 mg daily. If cytopenia persists for an additional 2 weeks, further reduce dose to 300 mg daily. If cytopenia persists for 4 weeks and is still unrelated to leukemia, withhold treatment until ANC ≥1 x 10<sup>9</sup>/L and platelets ≥20 x 10<sup>9</sup>/L, then resume treatment at 300 mg daily.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Nonhematologic toxicity (eg, severe edema):</i></b> Withhold treatment until toxicity resolves; may resume if appropriate (depending on initial severity of adverse event).</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic toxicity: If symptoms of DRESS (drug reaction with eosinophilia and systemic symptoms) occur, interrupt imatinib therapy and consider permanent discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypertension: If indicated, initiate appropriate antihypertensive therapy to reduce the risk for cardiovascular complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27918725','lexi-content-ref-36017568']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27918725','lexi-content-ref-36017568'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F181935"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F181948"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12618" href="/d/html/12618.html" rel="external">see "Imatinib: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Antiemetics may be recommended to prevent nausea and vomiting; imatinib doses &gt;260 mg/m<sup>2</sup>/day are associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49c961bb-ce39-4a65-be68-00d42b082a27">Acute lymphoblastic leukemia, Philadelphia chromosome-positive, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (ALL), Philadelphia chromosome-positive (Ph+), newly diagnosed:</b> Children and Adolescents: Oral: 340 mg/m<sup>2</sup>/day administered once daily; in combination with intensive chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24441288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24441288'])">Ref</a></span>); maximum daily dose: 600 mg/<b>day</b>; treatment may be continued until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00aca3dd-d6df-4728-b215-b4455bd86b37">Chronic myeloid leukemia, Philadelphia chromosome-positive, chronic phase, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia (CML), Philadelphia chromosome-positive (Ph+), chronic phase, newly diagnosed:</b> Children and Adolescents: Oral: 340 mg/m<sup>2</sup>/day administered once daily or in 2 divided doses; maximum daily dose: 600 mg/<b>day</b>. Treatment may be continued until disease progression or unacceptable toxicity. The optimal duration of therapy for CML in complete remission is not yet determined. Discontinuing CML treatment is not recommended unless part of a clinical trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19884523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19884523'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for nonhematologic adverse reactions:</b> Children and Adolescents: Withhold treatment until toxicity resolves; may resume if appropriate (depending on initial severity of adverse event).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for hematologic adverse reactions: </b>Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ALL Ph+ (newly diagnosed)</i>: Hematologic toxicity requiring dosage adjustments was not observed in the study. No major toxicities were observed with imatinib at 340 mg/m<sup>2</sup>/day in combination with intensive chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19805687']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19805687'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CML Ph+ (chronic phase):</i> If ANC &lt;1 x 10<sup>9</sup>/L and/or platelets &lt;50 x 10<sup>9</sup>/L: Withhold until ANC ≥1.5 x 10<sup>9</sup>/L and platelets ≥75 x 10<sup>9</sup>/L; resume treatment at previous dose. For recurrent neutropenia and/or thrombocytopenia, withhold until recovery and reinstitute treatment at a reduced dose as follows: If initial dose 340 mg/m<sup>2</sup>/day, reduce dose to 260 mg/m<sup>2</sup>/day.</p></div>
<div class="block dorp drugH1Div" id="F51113706"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (CrCl 40 to 59 mL/minute): There are no pediatric-specific recommendations; use caution; in adults with mild impairment, a maximum daily dose of 600 mg/<b>day</b> is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (CrCl 20 to 39 mL/minute): Decrease recommended starting dose by 50%; dose may be increased as tolerated; in adults with moderate impairment, a maximum daily dose of 400 mg/<b>day</b> is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (CrCl &lt;20 mL/minute): There are no pediatric-specific recommendations; use caution; in adults with severe impairment, a reduced dose of 100 mg/day has been tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18235116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18235116'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51113707"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Baseline:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment: No adjustment necessary</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: Reduce dose by 25%</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity during therapy:</i> Withhold treatment until toxicity resolves; may resume if appropriate (depending on initial severity of adverse event)</p>
<p style="text-indent:-2em;margin-left:6em;">If elevations of bilirubin &gt;3 times ULN or liver transaminases &gt;5 times ULN occur, withhold treatment until bilirubin &lt;1.5 times ULN and transaminases &lt;2.5 times ULN. Resume treatment at a reduced dose as follows: If current dose 340 mg/m<sup>2</sup>/day, reduce dose to 260 mg/m<sup>2</sup>/day; maximum daily dose range: 300 to 400 mg/<b>day</b></p></div>
<div class="block adr drugH1Div" id="F181898"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (7% to 11%), edema (11% to 86%; severe edema: 2% to 11%), peripheral edema (20% to 41%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (7% to 15%), dermatitis (29% to 39%), diaphoresis (9% to 13%), exfoliation of skin (≤50%), night sweats (13% to 17%), pruritus (7% to 26%), skin rash (≤50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention (62% to 76%; can be severe), hypoalbuminemia (12% to 21%), hypokalemia (6% to 13%), increased lactate dehydrogenase (43% to 60%), weight gain (5% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (7% to 19%), abdominal pain (3% to 57%; including abdominal cramps), anorexia (7% to 36%), constipation (8% to 16%), diarrhea (43% to 59%; grades 3/4: ≤5%), dysgeusia (7% to 13%), dyspepsia (≤27%), flatulence (10% to 25%), heartburn (≤11%), nausea (41% to 73%; grades 3/4: ≤5%), upper abdominal pain (14%), vomiting (23% to 58%; grades 3/4: ≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (32% to 35%; grades 3/4: 1% to 42%), granulocytopenia (≤16%), hemorrhage (3% to 53%; grades 3/4: 2% to 19%), hypoproteinemia (24% to 32%), leukopenia (5% to 20%; grades 3/4: &lt;1%), neutropenia (≤16%; grades 3/4: 3% to 48%), thrombocytopenia (grades 3/4: ≤33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (6% to 12%), increased serum alanine aminotransferase (17% to 34%), increased serum alkaline phosphatase (11% to 17%), increased serum aspartate aminotransferase (12% to 38%), increased serum bilirubin (11% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (7% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (14% to 28%), influenza (≤14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (8% to 12%), asthenia (≤75%), chills (≤11%), depression (3% to 15%), dizziness (5% to 19%), fatigue (≤75%), headache (8% to 37%), insomnia (9% to 15%), lethargy (≤75%), malaise (≤75%), pain (20% to 46%), paresthesia (5% to 12%), rigors (≤12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (9% to 40%), back pain (17%), limb pain (16%), muscle cramps (28% to 62%), muscle spasm (16% to 49%), musculoskeletal pain (adults: 38% to 49%; children: 21%), myalgia (9% to 32%), ostealgia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (5% to 11%), eyelid edema (19%), increased lacrimation (10% to 18%), periorbital edema (15% to 74%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (10% to 44%), nephrotoxicity (14%; including genitourinary)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (13% to 27%), dyspnea (6% to 21%), nasopharyngitis (1% to 31%), pharyngitis (≤15%), pharyngolaryngeal pain (18%), pneumonia (4% to 13%), sinusitis (4% to 11%), upper respiratory tract infection (3% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6% to 41%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cold extremity (≤1%), flushing, heart failure (≤1%), hypertension (4%), hypotension (≤1%), palpitations (5%), pericardial effusion (≤6%), Raynaud’s disease (≤1%), subdural hematoma (≤1%), syncope (≤1%), tachycardia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash (≤1%), cellulitis (≤1%), cheilitis (≤1%), ecchymoses (≤1%), erythema multiforme (≤1%), erythema of skin, exfoliative dermatitis (≤1%), folliculitis (≤1%), hyperpigmentation (≤1%), hypopigmentation (≤1%), hypotrichosis (≤1%), nail disease, onychoclasis (≤1%), psoriasis (≤1%), pustular rash (≤1%), skin photosensitivity (4% to 7%), urticaria (≤1%), xeroderma (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Anasarca, decreased libido (≤1%), dehydration (≤1%), gynecomastia (≤1%), heavy menstrual bleeding (≤1%), hypercalcemia (≤1%), hyperglycemia (≤1%), hyperkalemia (≤1%), hyperthyroidism (≤1%), hyperuricemia (≤1%), hypocalcemia (6%), hypomagnesemia (≤1%), hyponatremia (≤1%), hypophosphatemia (grade 3/4: 10%), hypothyroidism (≤1%), menstrual disease (≤1%), weight loss (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (10%), dysphagia (≤1%), eructation (≤1%), esophagitis (≤1%), gastric ulcer (≤1%), gastritis, gastroenteritis (10%), gastroesophageal reflux disease, gastrointestinal hemorrhage (2% to 8%; including gastric antral vascular ectasia), hematemesis (≤1%), increased appetite (≤1%), increased serum amylase, increased serum lipase (grades 3/4: 4%), melena (≤1%), oral mucosa ulcer (≤1%), pancreatitis (≤1%), stomatitis (≤10%), xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy (≤1%), erectile dysfunction (≤1%), hematuria (≤1%), nipple pain (≤1%), scrotal edema (≤1%), sexual disorder (≤1%), urinary frequency (≤1%), urinary tract infection (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bone marrow depression (≤1%), bruise (≤1%), eosinophilia, febrile neutropenia, hematoma (≤1%), lymphadenopathy (≤1%), lymphocytopenia (6% to 10%), nonthrombocytopenic purpura (≤1%), pancytopenia, petechia (≤1%), purpuric disease, thrombocytosis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (≤6%), hepatitis (≤1%), jaundice (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes simplex infection (≤1%), herpes zoster infection (≤1%), sepsis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (≤1%), hypoesthesia, intracranial hemorrhage (≤9%), memory impairment (≤1%), migraine (≤1%), myasthenia (≤1%), peripheral neuropathy (≤1%), restless leg syndrome (≤1%), sciatica (≤1%), tremor (≤1%), vertigo (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (≤1%), gout (≤1%), increased creatine phosphokinase in blood specimen, joint stiffness (≤1%), joint swelling, muscle rigidity (≤1%), panniculitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (≤1%), cataract (≤1%), conjunctival hemorrhage, conjunctivitis (5% to 8%), dry eye syndrome, eye irritation (≤1%), eye pain (≤1%), macular edema (≤1%), retinal hemorrhage (≤1%), sclera disease (hemorrhage: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (≤1%), tinnitus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (≤1%), renal pain (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, oropharyngeal pain (6%), pleural effusion (≤6%), pulmonary edema (≤6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, atrial fibrillation, cardiac arrhythmia, left ventricular dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, nail discoloration, Stevens-Johnson syndrome, Sweet syndrome, vesicular eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis, gastrointestinal obstruction, inflammatory bowel disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection<b>: </b>Fungal infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, increased intracranial pressure, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma, optic neuritis, papilledema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pneumonitis, pleuritic chest pain, pulmonary fibrosis, pulmonary hemorrhage, pulmonary hypertension</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac tamponade, cardiogenic shock, embolism, pericarditis, thrombosis<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Lichen planus, lichenoid eruption (keratosis), palmar-plantar erythrodysesthesia, pemphigus, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Pseudoporphyria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diverticulitis of the gastrointestinal tract, gastrointestinal irritation, gastrointestinal perforation</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ovarian cyst (hemorrhagic), ruptured corpus luteal cyst</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic microangiopathy, tumor hemorrhage, tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Brain edema</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Linear skeletal growth rate below expectation (children), myopathy, osteonecrosis (hip), rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Vitreous hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory failure, interstitial pulmonary disease, lower respiratory tract infection</p></div>
<div class="block coi drugH1Div" id="F181912"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to imatinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F181896"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: May cause bone marrow suppression (anemia, neutropenia, and thrombocytopenia), usually occurring within the first several months of treatment. Median duration of neutropenia is 2 to 3 weeks; median duration of thrombocytopenia is 2 to 4 weeks. In chronic myeloid leukemia (CML), cytopenias are more common in accelerated or blast phase than in chronic phase.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Severe heart failure (HF) and left ventricular dysfunction (LVD) have been reported (occasionally). Cardiac adverse events usually occur in patients with advanced age or comorbidities. With initiation of imatinib treatment, cardiogenic shock and/or LVD have been reported in patients with hypereosinophilic syndrome (HES) and cardiac involvement (reversible with systemic steroids, circulatory support and temporary cessation of imatinib). Echocardiogram and serum troponin monitoring may be considered in patients with HES/chronic eosinophilic leukemia (CEL) and in patients with myelodysplastic/myeloproliferative (MDS/MPD) disease or aggressive systemic mastocytosis associated with high eosinophil levels. Patients with high eosinophil levels and an abnormal echocardiogram or abnormal serum troponin level may benefit from prophylactic systemic steroids (for 1 to 2 weeks) with the initiation of imatinib. In a scientific statement from the American Heart Association, imatinib has been determined to be an agent that may either cause direct myocardial toxicity (rare) or exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported; recurrence has been described with rechallenge. Case reports of successful resumption at a lower dose (with corticosteroids and/or antihistamine) have been described; however, some patients may experience recurrent reactions. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported. Symptoms of DRESS include fever, severe skin eruption, lymphadenopathy, hematologic abnormalities (eosinophilia or atypical lymphocytes), and internal organ involvement. DRESS symptoms regressed upon discontinuation of therapy; however, symptoms recurred in all cases when rechallenged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Driving/heavy machinery: Caution is recommended while driving/operating motor vehicles and heavy machinery when taking imatinib; advise patients regarding side effects such as dizziness, blurred vision, or somnolence. Reports of accidents have been received, but it is unclear if imatinib has been the direct cause in any case.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention/edema: Imatinib is commonly associated with fluid retention, weight gain, and edema (risk increases with higher doses and age &gt;65 years); may be occasionally serious and lead to significant complications, including pleural effusion, pericardial effusion, pulmonary edema, and ascites. Rapid unexpected weight gain should be evaluated and managed appropriately. Use with caution in patients where fluid accumulation may be poorly tolerated, such as in cardiovascular disease (HF or hypertension) and pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: May cause GI irritation. There have been rare reports (including fatalities) of GI perforation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Severe hemorrhage (grades 3 and 4) has been reported with use, including GI hemorrhage and/or tumor hemorrhage. The incidence of hemorrhage is higher in patients with gastrointestinal stromal tumors (GIST) (GI tumors may have been hemorrhage source). Gastric antral vascular ectasia (a rare cause of gastrointestinal bleeding) has also been reported (Alshehry 2014; Saad Aldin 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity may occur; fatal hepatic failure and severe hepatic injury requiring liver transplantation have been reported with both short- and long-term use. Transaminase and bilirubin elevations, and acute liver failure have been observed with imatinib in combination with chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Imatinib is associated with a decline in renal function; may be associated with duration of therapy. The median estimated GFR declined from 85 mL/minute/1.73 m<sup>2</sup> at baseline to 75 mL/minute/1.73 m<sup>2</sup> at 12 months and to 69 mL/minute/1.73 m<sup>2</sup> at 60 months (in patients with newly diagnosed chronic myeloid leukemia and malignant GIST). Patients with risk factors for renal dysfunction (eg, preexisting renal impairment, diabetes mellitus, hypertension, congestive heart failure) may be at higher risk for nephrotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been reported in patients with acute lymphoblastic leukemia (ALL), CML eosinophilic leukemias, and GIST. Risk for TLS is higher in patients with a high tumor burden or high proliferation rate. Correct clinically significant dehydration and treat high uric acid levels prior to initiation of imatinib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric surgery: Imatinib exposure may be reduced in patients who have had gastric surgery (eg, bypass, major gastrectomy, or resection); monitor imatinib trough concentrations (Liu 2011; Pavlovsky 2009; Yoo 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Hypothyroidism has been reported in thyroidectomy patients who were receiving thyroid hormone replacement therapy prior to initiation of imatinib; monitor thyroid function. The average onset for imatinib-induced hypothyroidism is 2 weeks; consider doubling levothyroxine doses upon initiation of imatinib (Hamnvik 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older patients: The incidence of edema was increased with age ≥65 years in CML and GIST studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Growth retardation has been reported in children receiving imatinib for the treatment of CML; generally where treatment was initiated in prepubertal children; growth velocity was usually restored as pubertal age was reached (Shima 2011). Monitor growth closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Determine PDGFRb gene rearrangements status (for MDS/MPD), D816V c-kit mutation status (for aggressive systemic mastocytosis [ASM]), Philadelphia chromosome status for acute lymphoblastic leukemia and chronic myeloid leukemia, Kit (CD117)-positivity for GIST, and FIP1L1–platelet-derived growth factor (PDGF) receptor status for HES or CEL prior to initiating treatment.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878494"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Growth retardation has been reported in prepubescent children receiving imatinib for the treatment of CML (Bansal 2012; Rastogi 2012; Shima 2011); the majority of the preliminary data reported statistically significant decreases in height-SD (standard deviation) scores; less commonly reported are decreases in weight-SD scores or decreased BMI; incidence and extent of growth retardation as well as other related risk factors have not been fully characterized; reported incidence from reports is highly variable (48% to 71%), with onset during the first year of therapy and persisting with treatment. One report suggests that growth velocity was restored as pubertal age was reached; however, in other reports, patients did not have improvement in height velocity and genetically predicted adult heights were not achieved. Monitor growth closely.</p></div>
<div class="block foc drugH1Div" id="F181906"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gleevec: 100 mg, 400 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F181892"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F181915"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Gleevec Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $112.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $404.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Imatinib Mesylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.47 - $106.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $5.20 - $394.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867177"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gleevec: 100 mg, 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 400 mg</p></div>
<div class="block adm drugH1Div" id="F181909"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Imatinib is associated with a moderate or high emetic potential; antiemetics may be recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Administer with a meal and a large glass of water to minimize GI irritation. For daily dosing ≥800 mg, the 400 mg tablets should be used in order to reduce iron exposure. Do not crush tablets. Tablets may be dispersed in water or apple juice (using ~50 mL for 100 mg tablet, ~200 mL for 400 mg tablet); stir until dissolved and administer immediately. If necessary, an oral suspension may be prepared (see Extemporaneously Prepared). Avoid skin or mucous membrane contact with crushed tablets; if contact occurs, wash thoroughly. Avoid exposure to crushed tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">Doses ≤600 mg may be given once daily; 800 mg dose should be administered as 400 mg twice daily.</p></div>
<div class="block admp drugH1Div" id="F52613033"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics may be recommended to prevent nausea and vomiting; imatinib doses &gt;260 mg/m<sup>2</sup>/day are associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with a meal and a large glass of water. Do not crush tablets; avoid skin or mucous membrane contact with crushed tablets; if contact occurs, wash thoroughly.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets may be dispersed in water or apple juice (using ~50 mL for 100 mg tablet, ~200 mL for 400 mg tablet); stir until tablet dissolves and administer immediately. If necessary, an oral suspension may be prepared (see Extemporaneous Preparations). Dosing in pediatric patients may be once or twice daily when treating CML and once daily for Ph+ ALL.</p></div>
<div class="block hazard drugH1Div" id="F49132628"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F181908"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia: </b>Treatment of relapsed or refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of newly diagnosed Ph+ ALL in children (in combination with chemotherapy).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Aggressive systemic mastocytosis:</b> Treatment of aggressive systemic mastocytosis in adults without D816V mutation or with c-kit mutational status unknown. c-kit</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of newly diagnosed Ph+ chronic myeloid leukemia (CML) in chronic phase in adults and children.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alfa therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatofibrosarcoma protuberans: </b>Treatment of unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal stromal tumors: </b>Treatment of Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).</p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of Kit (CD117)–positive GIST following complete gross resection in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypereosinophilic syndrome and/or chronic eosinophilic leukemia: </b>Treatment of hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) in adult patients who have the FIP1L1–platelet-derived growth factor receptor (PDGFR) alpha fusion kinase (mutational analysis or fluorescent in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR alpha fusion kinase negative or unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic/Myeloproliferative diseases:</b> Treatment of myelodysplastic /myeloproliferative diseases associated with PDGFR gene rearrangements in adults.</p></div>
<div class="block off-label drugH1Div" id="F25474744"><span class="drugH1">Use: Off-Label: Adult</span><p>Chordoma, progressive, advanced, or metastatic expressing PDGFR beta and/or PDGF beta; Chronic myeloid leukemia, post-allogeneic hematopoietic cell transplantation; Desmoid tumor, locally advanced or progressive; Melanoma, advanced or metastatic, c-kit mutated tumors</p></div>
<div class="block mst drugH1Div" id="F3401645"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Imatinib may be confused with asciminib, avapritinib, axitinib, bosutinib, cabozantinib, capmatinib, dasatinib, enasidenib, erlotinib, fostamatinib, gefitinib, ibrutinib, idelalisib, infigratinib, ivosidenib, lapatinib, neratinib, nilotinib, PONATinib, regorafenib, ripretinib, SUNItinib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F181952"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), OCT1, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F181900"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May enhance the hepatotoxic effect of Imatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artesunate: Imatinib may increase serum concentrations of the active metabolite(s) of Artesunate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: Imatinib may increase the serum concentration of Asciminib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Astemizole.  Management: Avoid concomitant use of astemizole and moderate CYP3A4 inhibitors whenever possible. If combined, monitor closely for increased astemizole toxicities, especially for QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bedaquiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ceritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cisapride.  Management: Consider alternatives to this combination. Prescribing information for some moderate CYP3A4 inhibitors state coadministration with cisapride is contraindicated, while some others recommend monitoring and dose titration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Substrates (Narrow Therapeutic Index/Sensitive): Imatinib may increase the serum concentration of CYP2D6 Substrates (Narrow Therapeutic Index/Sensitive). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Imatinib. Management: Avoid use of imatinib and strong CYP3A4 inducers when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely. Doses up to 1200 mg/day (600 mg twice daily) have been used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Delamanid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with dexamethasone when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor clinical response closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May decrease the serum concentration of Imatinib. Imatinib may increase the serum concentration of Encorafenib. Management: Avoid this combination when possible. If combined, decrease the encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Entrectinib.  Management: Avoid moderate CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg/day if starting dose 200 mg; to 100 mg/day if starting dose 300 mg; to 200 mg if starting dose 400 mg or 600 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erythromycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fedratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May decrease serum concentrations of the active metabolite(s) of Imatinib. Specifically N-desmethylimatinib concentrations may be decreased. Gemfibrozil may decrease the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Imatinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibuprofen: May decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response. Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivosidenib.  Management: Avoid use of moderate CYP3A4 inhibitors with ivosidenib whenever possible. If combined, monitor for increased ivosidenib toxicities, including QTc prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lefamulin.  Management: Monitor for lefamulin adverse effects during coadministration of lefamulin tablets with moderate CYP3A4 inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Imatinib may decrease the serum concentration of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: Imatinib may increase the serum concentration of Lonafarnib. Lonafarnib may increase the serum concentration of Imatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a moderate CYP3A4 inhibitor. For those stable on mavacamten who are initiating a moderate CYP3A4 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methadone.  Management: If coadministration with moderate CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MiFEPRIStone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mobocertinib.  Management: Avoid use of moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May enhance the hepatotoxic effect of Imatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Red Yeast Rice. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ritonavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein.  For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 80 mg twice/day, or from 160 mg twice/day to 120 mg twice/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Conventional).  Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tafamidis: May increase the serum concentration of Imatinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Terfenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Imatinib may enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin.  Management: Consider using low-molecular-weight heparin or heparin instead of warfarin. If warfarin and imatinib must be coadministrered, increase monitoring of INR and for signs/symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F181926"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may reduce GI irritation. Grapefruit juice may increase imatinib plasma concentration. Management: Take with a meal and a large glass of water. Avoid grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>
<div class="block rep_considerations drugH1Div" id="F49307827"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;margin-left:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant. Patients who could become pregnant should use highly effective contraception (methods with &lt;1% pregnancy rates) during imatinib treatment and for 14 days after the last imatinib dose.</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Changes in menstrual patterns have been reported with tyrosine kinase inhibitor (TKI) therapy (Yu 2019).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Based on the mechanism of action, TKIs have the potential to adversely affect fertility by acting on receptors in the ovaries or testis; primarily when administered prior to puberty in males. Although there are cases showing difficulty conceiving, successful pregnancies have also been reported. Fertility data related to long term TKI use are limited. Recommendations are available for fertility preservation prior to TKI treatment (ASCO [Oktay 2018]; Madabhavi 2019; Rambhatla 2021).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Patients planning to become pregnant but currently receiving a TKI should minimize the risk of first trimester exposure (Rambhatla 2021). Discontinuing TKI therapy for chronic myeloid leukemia (CML) can be considered if the patient is eligible for a tumor-free remission, allowing a washout period before attempting to conceive (Baccarani 2019; ELN [Hochhaus 2020]; Madabhavi 2019). Because the time to conception can be highly variable, treatment may also be discontinued at the first positive pregnancy test, prior to organogenesis in select patients (Abruzzese 2020).</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">Outcome data following male use of imatinib prior to conception is available (Rambhatla 2021; Szakács 2020). Based on available data, imatinib does not need to be stopped prior to conception in patients diagnosed with CML planning to father a child (Abruzzese 2020; Baccarani 2019; BSH [Smith 2020]; ELN [Hochhaus 2020]).</p></div>
<div class="block pri drugH1Div" id="F181916"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Imatinib crosses the placenta (Ali 2009; Burwick 2017; Chelysheva 2018b; Russell 2007) and can be detected in newborn urine (Burwick 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of imatinib primarily for the treatment of chronic myeloid leukemia (CML) during pregnancy are available; adverse outcomes were reported in some cases, pregnancies without complications were also reported (Assi 2020; NTP 2013; Rambhatla 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of CML in pregnant patients should be individualized based on gestational age, hematologic parameters, and clinical condition at presentation. If pregnancy is detected in the first trimester in patients already on a tyrosine kinase inhibitor (TKI), treatment should be discontinued as soon as pregnancy is confirmed. Treatments other than a TKI are recommended in pregnant patients not eligible for a tumor-free remission. If a TKI is needed, imatinib may be considered after the first trimester. Close maternal and fetal monitoring is recommended (Abruzzese 2020; BSH [Smith 2020]; ELN [Hochhaus 2020]; Madabhavi 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F3339989"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Imatinib and its active metabolite are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The presence of imatinib in breast milk has been evaluated in multiple case reports; concentrations are variable; when evaluated, metabolite concentrations were higher in breast milk than maternal serum (Ali 2009; Burwick 2017; Chelysheva 2018a; Gambacorti-Passerini 2007; Kronenberger 2009; Russell 2007; Terao 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Imatinib breast milk concentrations were evaluated in 2 lactating patients diagnosed with chronic myeloid leukemia (CML) prior to pregnancy who restarted imatinib treatment after discontinuing breastfeeding. Breast milk was sampled at specified intervals from 1 to 24 hours after the maternal dose. In the first case, pre-pregnancy imatinib 400 mg/day was restarted 4 months postpartum. The maximum concentration of imatinib in breast milk (1,402 ng/mL) occurred 4 hours after the maternal dose. A second patient restarted imatinib 600 mg/day 1 month postpartum; the maximum concentration in breast milk (1,411 ng/mL) occurred 6 hours after the maternal imatinib dose (Chelysheva 2018a). A higher breast milk concentration was observed in a patient who initiated imatinib 400 mg/day at 21 weeks gestation. Postpartum sampling was conducted at various times following administration; the highest observed breast milk concentration (2,623 ng/mL) occurred 10 hours after the maternal dose on day 14 postpartum (Ali 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Concentrations of imatinib and the active metabolite CGP74588 were evaluated in a patient who restarted imatinib at 400 mg/day immediately postpartum. The highest breast milk concentrations were observed when sampled 51 hours after treatment started (imatinib 1,153 ng/mL, CGP74588 1,024 ng/mL). In comparison, maternal serum concentrations at the same time were 2,010 ng/mL (imatinib) and 284 ng/mL (CGP74588). Steady state concentrations in breast milk occurred after ~2 days. The infant was not breastfed (Kronenberger 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Imatinib concentrations in the colostrum were evaluated in a patient treated with imatinib 400 mg/day from 28 weeks gestation through the first 5 days postpartum. Imatinib samples obtained on the fifth day after delivery were 1,916 ng/mL (maternal blood), 663 ng/mL (breast milk), and 27 ng/mL (infant blood). The infant was breastfed for the first 5 days after birth and no adverse events were reported. The presence of the active metabolite was not evaluated (Terao 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk concentrations of imatinib and CGP74588 were also evaluated in a patient 4 weeks postpartum. The patient was receiving imatinib 400 mg/day for CML; maternal serum and breast milk were sampled from 1 to 9 hours after the dose. The steady state concentrations in breast milk were 1,100 to 1,400 ng/mL (imatinib) and 800 ng/mL (CGP74588). Steady state maternal serum concentrations were 3,000 to 3,200 ng/mL (imatinib) and 800 to 1,100 ng/mL (CGP74588). Authors of the report suggest that up to 10% of a therapeutic maternal imatinib dose could potentially be received by a breastfed infant (Gambacorti-Passerini 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 month after the last imatinib dose. Patients diagnosed with CML requiring a tyrosine kinase inhibitor may consider short term breastfeeding for the first 2 to 5 days postpartum to provide the benefits of colostrum to the newborn prior to starting or restarting therapy (Abruzzese 2020; Madabhavi 2019).</p></div>
<div class="block dic drugH1Div" id="F181917"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice.</p></div>
<div class="block mop drugH1Div" id="F181904"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC (weekly for first month, biweekly for second month, then periodically thereafter as clinically indicated), liver function tests (transaminases, bilirubin, and alkaline phosphatase; at baseline and monthly or as clinically indicated; more frequently [at least weekly] in patients with moderate to severe hepatic impairment [Ramanathan 2008]), renal function (at baseline and periodically thereafter), serum electrolytes (including calcium, phosphorus, potassium and sodium levels); bone marrow cytogenetics (in CML; at 6-, 12-, and 18 months). Evaluate pregnancy status prior to treatment in patients who could become pregnant. Monitor for fatigue, rapid weight gain, and edema/fluid status. Consider echocardiogram and serum troponin levels in patients with HES/CEL, and in patients with MDS/MPD or ASM with high eosinophil levels. In pediatric patients, also monitor serum glucose, albumin, and growth.</p>
<p style="text-indent:0em;margin-top:2em;">Gastric surgery (eg, bypass, major gastrectomy, or resection) patients: Monitor imatinib trough concentrations (Liu 2011; Pavlovsky 2009; Yoo 2010).</p>
<p style="text-indent:0em;margin-top:2em;">Thyroid function testing (Hamnvik 2011):</p>
<p style="text-indent:-2em;margin-left:4em;">Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months.</p>
<p style="text-indent:-2em;margin-left:4em;">Without preexisting thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2 to 3 months.</p>
<p style="text-indent:0em;margin-top:2em;">Monitor carefully for signs/symptoms of CHF in patients with at risk for cardiac failure or patients with preexisting cardiac disease. Monitor for signs/symptoms of GI irritation or perforation, dermatologic toxicities, and tumor lysis syndrome. Monitor adherence.</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Additional cardiovascular monitoring:</i> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; repeat assessment every 3 months for the first year and then every 6 to 12 months thereafter (ASCO [Armenian 2017]; ESC [Lyon 2022]). ECG at baseline. Consider baseline echocardiography in all patients; repeat every 3 months for high- and very high-risk patients (ESC [Lyon 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F181895"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Imatinib inhibits Bcr-Abl tyrosine kinase, the constitutive abnormal gene product of the Philadelphia chromosome in chronic myeloid leukemia (CML). Inhibition of this enzyme blocks proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as in fresh leukemic cells in Philadelphia chromosome positive CML. Also inhibits tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF), c-kit, and cellular events mediated by PDGF and SCF.</p></div>
<div class="block phk drugH1Div" id="F181911"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Parent drug and metabolite: ~95% to albumin and alpha<sub>1</sub>-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 (minor metabolism via CYP1A2, CYP2D6, CYP2C9, CYP2C19); primary metabolite (active): N-demethylated piperazine derivative (CGP74588); severe hepatic impairment (bilirubin &gt;3 to 10 times ULN) increases AUC by 45% to 55% for imatinib and its active metabolite, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 98%; may be decreased in patients who have had gastric surgery (eg, bypass, total or partial resection) (Liu 2011; Pavlovsky 2009; Yoo 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: Parent drug: ~18 hours; N-desmethyl metabolite: ~40 hours; Children: Parent drug: ~15 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (68% primarily as metabolites, 20% as unchanged drug); urine (13% primarily as metabolites, 5% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Adults: 10 L/hour/m<sup>2</sup> or 8 to 14 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51159828"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased 1.5- to 2-fold in patients with mild and moderate kidney impairment compared with patients with normal kidney function. Patients with severe kidney impairment experienced a 1.7-fold increase compared to patients with normal kidney function, although only two participants were included in the study (Gibbons 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with severe hepatic impairment have higher exposure to imatinib and its metabolite. The mean AUC of imatinib and its metabolite increased by ~45% and 55%, respectively, in patients with severe hepatic impairment as compared to patients with normal hepatic function. The mean C<sub>max</sub> of imatinib and its metabolite increased by ~63% and 56%, respectively, in patients with severe hepatic impairment as compared to patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F181918"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cemivil | Glivec | Imadair</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Agacel | Clinid | Datur | Glivec | Imatib | Imatinib elea | Imatinib gp pharm | Imatinova | Imatixa | Ingerinib | Iritech | Lematech | Matin | Mesinib | Ritor | Tagonib | Timab | Utinib | Vek | Ziatir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imagerolan | Imatinib 1a pharma | Imatinib Accord | Imatinib actavis | Imatinib Fresenius Kabi | Imatinib hcs | Imatinib koanaa | Imatinib mylan | Imatinib sandoz | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo imatinib | Cipla imatinib adult | Gilmat | Glivanib | Glivec | Imatinib | Imatinib an | Imatinib gh | Imatinib ranbaxy | Imatinib sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Enliven | Ibakin | Imanix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib ab | Imatinib Accord | Imatinib eg | Imatinib krka d.d. | Imatinib mylan | Imatinib sandoz | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Hronileucem | Imakrebin | Imatinib Accord | Imatinib actavis | Imatinib adipharm | Imatinib teva pharma | Imatinib Zentiva | Meaxin | Neoxell | Nibix</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Glimatin | Glivec | Leuphila | Mesilato de imatinibe | Pluto</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Glivec gist | Imatinib Accord | Imatinib devatis | Imatinib gist teva | Imatinib mylan | Imatinib sandoz | Imatinib teva | Imatinib Zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Imatinib cooper</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Imtib | Kadir | Redistra | Zeite</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Xin wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Biotinib | Glivec | Imatero | Imatin | Imatinib | Imavitae | Imuday | Lematin | Leusomin | Leutinib | Matib | Matinac | Zeite</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Imatinib Accord | Imatinib actavis | Imatinib aurovitas | Imatinib glenmark | Imatinib koanaa | Imatinib mylan | Imatinib pharmagen | Imatinib sandoz | Imatinib stada | Latib</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imanivec | Imatinib 1a pharma | Imatinib Accord | Imatinib al | Imatinib Amarox | Imatinib amneal | Imatinib aqvida | Imatinib axios | Imatinib basics | Imatinib beta | Imatinib cell pharm | Imatinib cipla | Imatinib denk | Imatinib devatis | Imatinib effect pharma | Imatinib glenmark | Imatinib Heumann | Imatinib hexal | Imatinib koanaa | Imatinib medicopharm | Imatinib mylan | Imatinib onkovis | Imatinib pensa | Imatinib puren | Imatinib ratiopharm | Imatinib ribosepharm | Imatinib riemser | Imatinib stada | Imatinib teva | Imatinib Zentiva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo imatinib | Glivec | Imatib | Imatinib | Matineb | Tinimab | Zeite</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Clinid | Glivec | Matinac | Timab | Zeite</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Glipox | Glivec | Imakrebin | Imatinib | Imatinib Accord | Imatinib sandoz | Imatinib sanoswiss | Imatinib teva | Imatinib Zentiva | Meaxin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Carcemia | Glivec | Imatib | Imatinib mylan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib amneal | Imatinib cipla | Imatinib dr. reddys | Imatinib farmalider | Imatinib kern pharma | Imatinib krka d.d. | Imatinib normon | Imatinib ranbaxy | Imatinib sandoz | Imatinib tarbis | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinate | Imatinib | Imatinib denk | Imatinib mesylate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib avansor | Imatinib koanaa | Imatinib krka d.d. | Imatinib mylan | Imatinib orion | Imatinib ratiopharm | Imatinib sandoz | Imatinib stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Imatinib Accord | Imatinib arrow lab | Imatinib bgr | Imatinib cristers | Imatinib eg | Imatinib hcs | Imatinib krka d.d. | Imatinib mylan | Imatinib ranbaxy | Imatinib sandoz | Imatinib teva | Imatinib Zentiva | Imatinib zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Nibix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatek | Imatinib | Imatinib aenorasis | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imakrebin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Astrea | Glivec | Imakrebin | Imatinib Accord | Imatinib cipla | Imatinib sandoz | Imatinib teva | Meaxin | Neopax | Nibix | Plivatinib</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib cipla | Imatinib diamedia | Imatinib mylan | Imatinib onkogen | Imatinib pharmacenter | Imatinib sandoz | Imatinib stada | Imatinib teva | Latib | Nibix</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatero | Tibisan | Tinibat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Imatinib krka d.d.</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Glivec</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Altanib | Cadinib | Celonib | Chemotinib | Glivec | Imalek | Imanex | Imanib | Imatero | Imatib | Imatinate | Imatirel | Imicap | Levin | Lupinib | Mitinab | Mytinib | Samitib | Stritinib | Temsan | Unitinib | Veenat | Zealata | Zimitib</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Mylaukim</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imanivec | Imatinib Accord | Imatinib Aurobindo | Imatinib doc | Imatinib dr reddys | Imatinib eg | Imatinib Fresenius Kabi | Imatinib mylan | Imatinib mylan pharma | Imatinib ranbaxy | Imatinib reddy | Imatinib sandoz | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cemivil | Glivec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Imatinib chemiphar | Imatinib dsep | Imatinib nipro | Imatinib nskk | Imatinib ohara | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Glomatinib | Ibakin | Imasil | Imatib | Sagitta</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Carevec | Glima | Glinib | Glitive | Glivec | Glotib | Glybulen | Imatib | Inivec | Jtinib | Leukivec | Leukovec | Newtinib | Prevec</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Glivec</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo imatinib | Cemivil | Glimatinib | Glivec | Imatib | Imatinib elea | Sagitta</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Glipox | Glivec | Imakrebin | Imatinib | Imatinib Accord | Imatinib sanoswiss | Meapax | Meaxin | Yleris</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib eg | Imatinib mylan | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imakrebin | Imatinib Accord | Imatinib Grindeks | Imatinib sanoswiss | Imatinib teva | Imatinib Zentiva | Itivas | Meaxin | Tibaldix</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatec | Imatinib cooper | Imatinib zenith</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Chamkila | Detepol | Glivec | Intici | Invicarin | Protyrin | Survtyk | Timedrib</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Accord imatinib | Apo imatinib | Glivec | Trevive</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Glomatinib | Imatinib denk</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib | Imatinib krka | Imatinib sandoz | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib actavis | Imatinib cipla | Imatinib mylan | Imatinib sandoz | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Aft | Imatinib mesylate | Imatinib Rex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Celonib 400 | Glivec | Imatinib | Imitim | Milatus | Timab | Tinibe | Tykonib | Zeite</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cytonib | Glivec | Imalek | Imanorm</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Im tab | Imatib</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imakrebin | Imatenil | Imatinib | Imatinib Accord | Imatinib actavis | Imatinib apotex | Imatinib aurovitas | Imatinib polfa | Imatinib teva | Imatinib Zentiva | Leutipol | Meaxin | Nibix | Telux</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gleevec | Imatinib mesylate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib farmoz | Imatinib Fresenius Kabi | Imatinib krka d.d. | Imatinib mylan | Imatinib normon | Imatinib sandoz | Imatinib teva | Imatinib Zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib cipla | Imatinib intas | Imatinib khairi | Imatinib libra | Imatinib mesilato imedic | Imatinib tuteur | Matineb | Tagonib | Zeite | Ziatir</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Ketova</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Egitinid | Glivec | Imakrebin | Imatinib Accord | Imatinib actavis | Imatinib glenmark | Imatinib terapia | Imatinib teva | Imatinib Zentiva | Meaxin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Albitinib | Citonib | Genfatinib | Gistamel | Glemyhib | Glivec | Iglib | Imagliv | Imatib | Imatinib | Imatinib grindex | Imatinib medac | Imatinib sigardis | Imatinib teva | Imatinib tl | Imvec | Neopax | Philachromin | Philachromin FS</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo imatinib | Cemivil | Glivec | Imatinib spc | Imutin | Ketova</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib actavis | Imatinib cipla | Imatinib Fresenius Kabi | Imatinib Grindeks | Imatinib koanaa | Imatinib krka d.d. | Imatinib mylan | Imatinib sandoz | Imatinib stada | Imatinib teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alvotinib | Glivec | Imatinib Aft | Imatiqual Fc | Vativio</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib Accord | Imatinib stada | Imatinib teva | Meaxin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatinib actavis | Imatinib generics | Imatinib glenmark | Imatinib sandoz | Imatinib stada | Imatinib teva | Imatinib Zentiva | Meaxin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alvotinib | Glivec | Imatinib | Imnib</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cemivil | Glivec | Imatinib | Imatinib neapolis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Glivon | Imagliv | Imatenil | Imatis | Imavec | Pantikor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alvotinib | Glivec | Ivic | Leevk | Slivec</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alvotinib | Glivec | Imatero | Imatib | Imatinib actavis | Imatinib grindex | Imatinib teva | Imatinib Zentiva | Neopax | Redivec</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Imatib | Imatinate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatin | Kimatinib | Timab</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Matinac</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ginib | Gleetib | Gleevec | Imalek | Imatinib | Imatinib Accord | Imatinib adco | Imatinib sandoz | Imavec | Mivesta | Sunmatin | Vativio</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Glivec | Imatis</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33194164">
<a name="33194164"></a>Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. <i>Ther Adv Hematol</i>. 2020;11:2040620720966120. doi:10.1177/2040620720966120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/33194164/pubmed" id="33194164" target="_blank">33194164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19083009">
<a name="19083009"></a>Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. <i>Arch Gynecol Obstet</i>. 2009;280(2):169-175. doi:10.1007/s00404-008-0861-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19083009/pubmed" id="19083009" target="_blank">19083009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356253">
<a name="25356253"></a>Alshehry NF, Kortan P, Lipton JH. Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia. <i>Clin Case Rep</i>. 2014;2(3):77-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/25356253/pubmed" id="25356253" target="_blank">25356253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33283580">
<a name="33283580"></a>Assi R, Kantarjian H, Keating M, et al. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience. <i>Leuk Lymphoma</i>. 2021;62(4):909-917. doi:10.1080/10428194.2020.1849672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/33283580/pubmed" id="33283580" target="_blank">33283580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17449798">
<a name="17449798"></a>Atallah E, Durand JB, Kantarjian H, et al. Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy. <i>Blood</i>. 2007;110(4):1233-1237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17449798/pubmed" id="17449798" target="_blank">17449798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31869412">
<a name="31869412"></a>Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Adv</i>. 2019;3(24):4280-4290. doi:10.1182/bloodadvances.2019000865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/31869412/pubmed" id="31869412" target="_blank">31869412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884523">
<a name="19884523"></a>Baccarani M, Cortes J, Pane F, et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>J Clin Oncol</i>. 2009;27(35):6041-6051.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19884523/pubmed" id="19884523" target="_blank">19884523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052850">
<a name="22052850"></a>Bansal D, Shava U, Varma N, et al. Imatinib Has Adverse Effect on Growth in Children With Chronic Myeloid Leukemia. <i>Pediatr Blood Cancer</i>. 2012;59(3):481-484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22052850/pubmed" id="22052850" target="_blank">22052850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20606084">
<a name="20606084"></a>Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. <i>J Clin Oncol. </i>2010;28(22):3644-3452. doi:10.1200/JCO.2010.28.1287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20606084/pubmed" id="20606084" target="_blank">20606084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16687713">
<a name="16687713"></a>Berman E, Nicolaides M, Maki RG, et al. Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate. <i>N Engl J Med</i>. 2006;354(19):2006-2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16687713/pubmed" id="16687713" target="_blank">16687713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20332334">
<a name="20332334"></a>Bilgi N, Bell K, Ananthakrishnan AN, et al. Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity. <i>Ann Pharmacother</i>. 2010;44(5):926-928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20332334/pubmed" id="20332334" target="_blank">20332334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11271979">
<a name="11271979"></a>Brunstein CG, McGlave PB. The Biology and Treatment of Chronic Myelogenous Leukemia. <i>Oncology</i>. 2001;15:23-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11271979/pubmed" id="11271979" target="_blank">11271979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28383372">
<a name="28383372"></a>Burwick RM, Kuo K, Brewer D, Druker BJ. Maternal, fetal, and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy. <i>Obstet Gynecol</i>. 2017;129(5):831-834. doi:10.1097/AOG.0000000000001972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28383372/pubmed" id="28383372" target="_blank">28383372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17119111">
<a name="17119111"></a>Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic Administration of Imatinib After Hematopoietic Cell Transplantation for High-Risk Philadelphia Chromosome-Positive Leukemia. <i>Blood</i>. 2007;109(7):2791-2793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17119111/pubmed" id="17119111" target="_blank">17119111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21642685">
<a name="21642685"></a>Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a Therapeutic Target in Metastatic Melanoma. <i>JAMA</i>. 2011;305(22):2327-2334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21642685/pubmed" id="21642685" target="_blank">21642685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28362562">
<a name="28362562"></a>Casali PG, Zalcberg J, Le Cesne A, et al; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. <i>J Clin Oncol</i>. 2017;35(15):1713-1720. doi:10.1200/JCO.2016.71.0228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28362562/pubmed" id="28362562" target="_blank">28362562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25878120">
<a name="25878120"></a>Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i>. 2015;125(24):3711-3719. doi:10.1182/blood-2015-02-627935<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/25878120/pubmed" id="25878120" target="_blank">25878120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19012999">
<a name="19012999"></a>Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. Imatinib in the treatment of nephrogenic systemic fibrosis. <i>Am J Kidney Dis</i>. 2009;53(1):129-32. doi:10.1053/j.ajkd.2008.08.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19012999/pubmed" id="19012999" target="_blank">19012999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29755704">
<a name="29755704"></a>Chelysheva E, Aleshin S, Polushkina E, et al. Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review. <i>Mediterr J Hematol Infect Dis</i>. 2018a;10(1):e2018027. doi:10.4084/MJHID.2018.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/29755704/pubmed" id="29755704" target="_blank">29755704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703026">
<a name="28703026"></a>Chelysheva E, Turkina A, Polushkina E, et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. <i>Leuk Lymphoma</i>. 2018b;59(3):733-738. doi:10.1080/10428194.2017.1347929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28703026/pubmed" id="28703026" target="_blank">28703026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20724445">
<a name="20724445"></a>Chugh R, Wathen JK, Patel SR, et al. Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research Through Collaboration (SARC) Trial. <i>Clin Cancer Res</i>. 2010;16(19):4884-4891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20724445/pubmed" id="20724445" target="_blank">20724445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22244674">
<a name="22244674"></a>Cornelison M, Jabbour EJ, Welch MA. Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner. <i>J Support Oncol</i>. 2012;10(1):14-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22244674/pubmed" id="22244674" target="_blank">22244674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20008622">
<a name="20008622"></a>Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. <i>J Clin Oncol</i>. 2010;28(3):424-430. doi:10.1200/JCO.2009.25.3724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20008622/pubmed" id="20008622" target="_blank">20008622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33275749">
<a name="33275749"></a>Cortes J. How to manage CML patients with comorbidities. <i>Hematology Am Soc Hematol Educ Program</i>. 2020;2020(1):237-242. doi:10.1182/hematology.2020006911<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/33275749/pubmed" id="33275749" target="_blank">33275749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15297408">
<a name="15297408"></a>DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended Follow-Up of Patients Treated With Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse After Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism Without Graft-Versus-Host Disease. <i>Clin Cancer Res</i>. 2004;10(15):5065-5071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15297408/pubmed" id="15297408" target="_blank">15297408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16624552">
<a name="16624552"></a>Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and Dose Selection for Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors. <i>Eur J Cancer</i>. 2006;42(8):1093-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16624552/pubmed" id="16624552" target="_blank">16624552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16198662">
<a name="16198662"></a>de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine. <i>Clin Pharmacol Ther</i>. 2005;78(4):433-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16198662/pubmed" id="16198662" target="_blank">16198662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062730">
<a name="17062730"></a>de Labarthe A, Rousselot P, Huguet-Rigal F, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. <i>Blood.</i> 2007;109(4):1408-1413. doi:10.1182/blood-2006-03-011908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17062730/pubmed" id="17062730" target="_blank">17062730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19303137">
<a name="19303137"></a>Dematteo RP, Ballman KV, Antonescu CR, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2009;373(9669):1097-1104. doi:10.1016/S0140-6736(09)60500-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19303137/pubmed" id="19303137" target="_blank">19303137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449525">
<a name="16449525"></a>Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a Potential Antiresorptive Therapy for Bone Disease. <i>Blood</i>. 2006;107(11):4334-4337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16449525/pubmed" id="16449525" target="_blank">16449525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16779792">
<a name="16779792"></a>Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib Mesylate in the Treatment of Systemic Mastocytosis: A Phase II Trial. <i>Cancer</i>. 2006;107(2):345-351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16779792/pubmed" id="16779792" target="_blank">16779792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11287973">
<a name="11287973"></a>Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia With the Philadelphia Chromosome. <i>N Engl J Med</i>. 2001;344(14):1038-1042.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11287973/pubmed" id="11287973" target="_blank">11287973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11287972">
<a name="11287972"></a>Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. <i>N Engl J Med</i>. 2001;344(14):1031-1037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11287972/pubmed" id="11287972" target="_blank">11287972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22850565">
<a name="22850565"></a>Eechoute K, Fransson MN, Reyners AK, et al. A Long-Term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. <i>Clin Cancer Res</i>. 2012;18(20):5780-5787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22850565/pubmed" id="22850565" target="_blank">22850565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28095277">
<a name="28095277"></a>Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. <i>J Clin Oncol</i>. 2017;35(3):298-305. doi:10.1200/JCO.2016.68.2914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28095277/pubmed" id="28095277" target="_blank">28095277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Farag.1">
<a name="Farag.1"></a>Farag S, Somaiah N, Chooi H, et al. Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients (abstract). <i>J Clin Oncol</i> 34, 2016 (suppl; abstr 11011). http://meetinglibrary.asco.org/content/164473-176 Accessed on Sept 13, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422402">
<a name="21422402"></a>Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>J Natl Cancer Inst</i>. 2011;103(7):553-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21422402/pubmed" id="21422402" target="_blank">21422402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17284536">
<a name="17284536"></a>Gambacorti-Passerini CB, Tornaghi L, Marangon E, et al. Imatinib concentrations in human milk. <i>Blood</i>. 2007;109(4):1790. doi:10.1182/blood-2006-08-039545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17284536/pubmed" id="17284536" target="_blank">17284536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18235116">
<a name="18235116"></a>Gibbons J, Egorin MJ, Ramanathan RK, et al; National Cancer Institute Organ Dysfunction Working Group. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. <i>J Clin Oncol</i>. 2008;26(4):570-576. doi:10.1200/JCO.2007.13.3819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18235116/pubmed" id="18235116" target="_blank">18235116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gleevec.1">
<a name="Gleevec.1"></a>Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gleevec.2">
<a name="Gleevec.2"></a>Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gleevec.3">
<a name="Gleevec.3"></a>Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gleevec.4">
<a name="Gleevec.4"></a>Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; received September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gleevec.5">
<a name="Gleevec.5"></a>Gleevec (imatinib) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15070659">
<a name="15070659"></a>Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha Fusion Tyrosine Kinase in Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia: Implications for Diagnosis, Classification, and Management. <i>Blood</i>. 2004;103(8):2879-2891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15070659/pubmed" id="15070659" target="_blank">15070659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, Marqusee E. Thyroid Dysfunction From Antineoplastic Agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10965782">
<a name="10965782"></a>Hehlmann R, Hochhaus A, Berger U, et al. Current Trends in the Management of Chronic Myelogenous Leukemia. <i>Ann Hematol</i>. 2000;79:345-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/10965782/pubmed" id="10965782" target="_blank">10965782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24297946">
<a name="24297946"></a>Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. <i>J Clin Oncol</i>. 2014;32(5):415-423. doi:10.1200/JCO.2013.49.9020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/24297946/pubmed" id="24297946" target="_blank">24297946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18955451">
<a name="18955451"></a>Heinrich MC, Owzar K, Corless CL, et al. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. <i>J Clin Oncol</i>. 2008;26(33):5360-5367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18955451/pubmed" id="18955451" target="_blank">18955451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234522">
<a name="16234522"></a>Hess G, Bunjes D, Siegert W, et al. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. <i>J Clin Oncol</i>. 2005;23(30):7583-7593.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16234522/pubmed" id="16234522" target="_blank">16234522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27460678">
<a name="27460678"></a>Hino A, Yoshida H, Tada Y, et al. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia. <i>Int J Hematol</i>. 2016;104(5):605-611. doi:10.1007/s12185-016-2071-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27460678/pubmed" id="27460678" target="_blank">27460678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32127639">
<a name="32127639"></a>Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. <i>Leukemia</i>. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/32127639/pubmed" id="32127639" target="_blank">32127639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28273028">
<a name="28273028"></a>Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. <i>N Engl J Med</i>. 2017;376(10):917-927. doi:10.1056/NEJMoa1609324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/28273028/pubmed" id="28273028" target="_blank">28273028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19282833">
<a name="19282833"></a>Hochhaus A, O'Brien SG, Guilhot F, et al. Six-Year Follow-Up of Patients Receiving Imatinib for the First-Line Treatment of Chronic Myeloid Leukemia. <i>Leukemia</i>. 2009;23(6):1054-1061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19282833/pubmed" id="19282833" target="_blank">19282833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23775962">
<a name="23775962"></a>Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. <i>J Clin Oncol</i>. 2013;31(26):3182-3190. doi:10.1200/JCO.2012.47.7836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/23775962/pubmed" id="23775962" target="_blank">23775962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21346253">
<a name="21346253"></a>Ibrahim AR, Eliasson L, Apperley JF, et al. Poor Adherence is the Main Reason for Loss of CCyR and Imatinib Failure for Chronic Myeloid Leukemia Patients on Long-Term Therapy. <i> Blood</i>. 2011;117(14):3733-3736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21346253/pubmed" id="21346253" target="_blank">21346253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.1">
<a name="EMA.1"></a>Imatinib Teva (imatinib) film-coated tablets [European Medicines Agency product information]. https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-teva. Accessed August 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29521048">
<a name="29521048"></a>Janeczko-Czarnecka M, Krawczuk-Rybak M, Karpińska-Derda I, et al. Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas. <i>Adv Clin Exp Med</i>. 2018;27(1):91-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/29521048/pubmed" id="29521048" target="_blank">29521048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22453568">
<a name="22453568"></a>Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. <i>JAMA</i>. 2012;307(12):1265-1272. doi:10.1001/jama.2012.347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22453568/pubmed" id="22453568" target="_blank">22453568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11287975">
<a name="11287975"></a>Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient With a Metastatic Gastrointestinal Stromal Tumor. <i>N Engl J Med</i>. 2001;344(14):1052-1056.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11287975/pubmed" id="11287975" target="_blank">11287975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12176876">
<a name="12176876"></a>Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. <i>Blood</i>. 2002a;100(5):1590-1595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/12176876/pubmed" id="12176876" target="_blank">12176876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11870241">
<a name="11870241"></a>Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. <i>N Engl J Med</i>. 2002b;346:645-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/11870241/pubmed" id="11870241" target="_blank">11870241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16862153">
<a name="16862153"></a>Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. <i>Nat Med</i>. 2006;12(8):908-916.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16862153/pubmed" id="16862153" target="_blank">16862153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19462170">
<a name="19462170"></a>Kronenberger R, Schleyer E, Bornhäuser M, Ehninger G, Gattermann N, Blum S. Imatinib in breast milk. <i>Ann Hematol</i>. 2009;88(12):1265-1266. doi:10.1007/s00277-009-0754-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19462170/pubmed" id="19462170" target="_blank">19462170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18256322">
<a name="18256322"></a>Larson RA, Druker BJ, Guilhot F, et al. Imatinib Pharmacokinetics and its Correlation With Response and Safety in Chronic-Phase Chronic Myeloid Leukemia: A Subanalysis of the IRIS Study. <i>Blood</i>. 2008;111(8):4022-4028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18256322/pubmed" id="18256322" target="_blank">18256322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20864406">
<a name="20864406"></a>Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumours After 3 Years of Treatment: An Open-Label Multicentre Randomised Phase 3 Trial. <i>Lancet Oncol</i>. 2010;11(10):942-949.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20864406/pubmed" id="20864406" target="_blank">20864406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19620483">
<a name="19620483"></a>Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of Progression as Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial. <i>J Clin Oncol</i>. 2009;27(24):3969-3974.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19620483/pubmed" id="19620483" target="_blank">19620483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27543577">
<a name="27543577"></a>Li Q, Liu Z, Kolli S, et al. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspension. <i>Am J Health Syst Pharm.</i> 2016;73(17):1331-1337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27543577/pubmed" id="27543577" target="_blank">27543577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21133728">
<a name="21133728"></a>Liu H, Artz AS. Reduction of Imatinib Absorption After Gastric Bypass Surgery. <i>Leuk Lymphoma</i>. 2011;52(2):310-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21133728/pubmed" id="21133728" target="_blank">21133728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31584851">
<a name="31584851"></a>Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy outcomes in chronic myeloid leukemia: a single center experience. <i>J Glob Oncol</i>. 2019;5:1-11. doi:10.1200/JGO.18.00211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/31584851/pubmed" id="31584851" target="_blank">31584851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20965785">
<a name="20965785"></a>Mahon FX, Réa D, Guilhot J, et al. Discontinuation of Imatinib in Patients With Chronic Myeloid Leukaemia Who Have Maintained Complete Molecular Remission for at Least 2 Years: the Prospective, Multicentre Stop Imatinib (STIM) Trial. <i>Lancet Oncol</i>. 2010;11(11):1029-1035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20965785/pubmed" id="20965785" target="_blank">20965785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21310760">
<a name="21310760"></a>Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. <i>Ann Oncol</i>. 2011;22(9):2073-2079.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21310760/pubmed" id="21310760" target="_blank">21310760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15681532">
<a name="15681532"></a>McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated with Imatinib: Imatinib Target Exploration Consortium Study B2225. <i>J Clin Oncol</i>. 2005;23(4):866-873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15681532/pubmed" id="15681532" target="_blank">15681532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30601909">
<a name="30601909"></a>Navarrete-Dechent C, Mori S, Barker CA, Dickson MA, Nehal KS. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. <i>JAMA Dermatol.</i> 2019;155(3):361-369. doi:10.1001/jamadermatol.2018.4940<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/30601909/pubmed" id="30601909" target="_blank">30601909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27403097">
<a name="27403097"></a>Niikura R, Serizawa T, Yamada A, et al. Safety of regular-dose imatinib therapy in patients with gastrointestinal stromal tumors undergoing dialysis. <i>Case Rep Gastroenterol</i>. 2016;10(1):17-23. doi:10.1159/000443267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27403097/pubmed" id="27403097" target="_blank">27403097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17881635">
<a name="17881635"></a>Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation Imatinib as a Strategy to Postpone the Requirement for Immunotherapy in Patients Undergoing Reduced-Intensity Allografts for Chronic Myeloid Leukemia. <i>Blood</i>. 2007;110(13):4614-4617.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17881635/pubmed" id="17881635" target="_blank">17881635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17429836">
<a name="17429836"></a>Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib Compared With Chemotherapy as Front-Line Treatment of Elderly Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). <i>Cancer</i>. 2007;109(10):2068-2076.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17429836/pubmed" id="17429836" target="_blank">17429836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16680756">
<a name="16680756"></a>Ozdemir E, Koc Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. <i>Am J Hematol</i>. 2006;81(6):474. doi:10.1002/ajh.20620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16680756/pubmed" id="16680756" target="_blank">16680756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15883819">
<a name="15883819"></a>Pappas P, Karavasilis V, Briasoulis E, Pavlidis N, Marselos M. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. <i>Cancer Chemother Pharmacol</i>. 2005;56(4):358-360. doi:10.1007/s00280-005-1031-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/15883819/pubmed" id="15883819" target="_blank">15883819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19698017">
<a name="19698017"></a>Pavlovsky C, Egorin MJ, Shah DD, et al. Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient With Chronic Myeloid Leukemia. <i>Pharmacotherapy</i>. 2009;29(9):1152-1156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19698017/pubmed" id="19698017" target="_blank">19698017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20622000">
<a name="20622000"></a>Penel N, Le Cesne A, Bui BN, et al. Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC/French Sarcoma Group Phase II trial With a Long-Term Follow-up. <i>Ann Oncol</i>. 2011;22(2):452-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20622000/pubmed" id="20622000" target="_blank">20622000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18322153">
<a name="18322153"></a>Pye SM, Cortes J, Ault P, et al. The Effects of Imatinib on Pregnancy Outcome. <i>Blood</i>. 2008;111(12):5505-5508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18322153/pubmed" id="18322153" target="_blank">18322153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18235115">
<a name="18235115"></a>Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. <i>J Clin Oncol</i>. 2008;26(4):563-569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/18235115/pubmed" id="18235115" target="_blank">18235115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33826052">
<a name="33826052"></a>Rambhatla A, Strug MR, De Paredes JG, Cordoba Munoz MI, Thakur M. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. <i>J Assist Reprod Genet</i>. 2021;38(8):1897-1908. doi:10.1007/s10815-021-02181-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/33826052/pubmed" id="33826052" target="_blank">33826052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22378641">
<a name="22378641"></a>Rastogi MV, Stork L, Druker B, et al, "Imatinib Mesylate Causes Growth Deceleration in Pediatric Patients With Chronic Myelogenous Leukemia," <i>Pediatr Blood Cancer</i>, 2012, 59(5):840-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22378641/pubmed" id="22378641" target="_blank">22378641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377606">
<a name="17377606"></a>Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. <i>J Perinatol</i>. 2007;27(4):241-243. doi:10.1038/sj.jp.7211665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/17377606/pubmed" id="17377606" target="_blank">17377606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20194851">
<a name="20194851"></a>Rutkowski P, Van Glabbeke M, Rankin CJ, et al; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. <i>J Clin Oncol.</i> 2010;28(10):1772-1779. doi:10.1200/JCO.2009.25.7899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20194851/pubmed" id="20194851" target="_blank">20194851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22422898">
<a name="22422898"></a>Saad Aldin E, Mourad F, Tfayli A. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review. <i>Jpn J Clin Oncol</i>. 2012;42(5):447-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22422898/pubmed" id="22422898" target="_blank">22422898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19805687">
<a name="19805687"></a>Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. <i>J Clin Oncol</i>. 2009;27(31):5175-5181. doi:10.1200/JCO.2008.21.2514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19805687/pubmed" id="19805687" target="_blank">19805687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24441288">
<a name="24441288"></a>Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. <i>Leukemia</i>. 2014;28(7):1467-1471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/24441288/pubmed" id="24441288" target="_blank">24441288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21592517">
<a name="21592517"></a>Shima H, Tokuyama M, Tanizawa A, et al. Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children With Chronic Myeloid Leukemia. <i>J Pediatr</i>. 2011;159(4):676-681.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21592517/pubmed" id="21592517" target="_blank">21592517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34894374">
<a name="34894374"></a>Singh AK, Hussain S, Ahmed R, et al. Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients. <i>Nephrology (Carlton)</i>. 2022;27(4):318-326. doi:10.1111/nep.14014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/34894374/pubmed" id="34894374" target="_blank">34894374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32734668">
<a name="32734668"></a>Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. <i>Br J Haematol</i>. 2020;191(2):171-193. doi:10.1111/bjh.16971<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/32734668/pubmed" id="32734668" target="_blank">32734668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22331945">
<a name="22331945"></a>Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II Study of Imatinib in Advanced Chordoma. <i>J Clin Oncol</i>. 2012;30(9):914-920.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22331945/pubmed" id="22331945" target="_blank">22331945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19570961">
<a name="19570961"></a>Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. <i>Ann Oncol</i>. 2009;20(11):1886-1894. doi:10.1093/annonc/mdp210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/19570961/pubmed" id="19570961" target="_blank">19570961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33270732">
<a name="33270732"></a>Szakács Z, Hegyi PJ, Farkas N, et al. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a systematic review. <i>PLoS One</i>. 2020;15(12):e0243045. doi:10.1371/journal.pone.0243045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/33270732/pubmed" id="33270732" target="_blank">33270732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22960387">
<a name="22960387"></a>Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. <i>Biol Blood Marrow Transplant.</i> 2013;19(1):150-155. doi:10.1016/j.bbmt.2012.08.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22960387/pubmed" id="22960387" target="_blank">22960387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32787559">
<a name="32787559"></a>Terao R, Nii M, Asai H, et al. Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy. <i>J Oncol Pharm Pract</i>. 2021;27(3):756-760. doi:10.1177/1078155220948942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/32787559/pubmed" id="32787559" target="_blank">32787559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551133">
<a name="14551133"></a>Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103(12):4396-4407. doi:10.1182/blood-2003-08-2958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/14551133/pubmed" id="14551133" target="_blank">14551133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20564631">
<a name="20564631"></a>Tong WG, Kantarjian H, O'Brien S, et al. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. <i>Cancer</i>. 2010;116(13):3152-3159. doi:10.1002/cncr.25071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20564631/pubmed" id="20564631" target="_blank">20564631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21078547">
<a name="21078547"></a>von Mehren M, Widmer N. Correlations Between Imatinib Pharmacokinetics, Pharmacodynamics, Adherence, and Clinical Response in Advanced Metastatic Gastrointestinal Stromal Tumor (GIST): An Emerging Role for Drug Blood Level Testing? <i>Cancer Treat Rev</i>. 2011;37(4):291-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/21078547/pubmed" id="21078547" target="_blank">21078547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22728491">
<a name="22728491"></a>Wada Y, Ogata H, Misawa S, Shimada A, Kinugasa E. A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate. <i>Intern Med</i>. 2012;51(12):1561-1565. doi:10.2169/internalmedicine.51.6709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/22728491/pubmed" id="22728491" target="_blank">22728491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16344315">
<a name="16344315"></a>Yanada M, Takeuchi J, Sugiura I, et al. High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group. <i>J Clin Oncol</i>. 2006;24(3):460-466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/16344315/pubmed" id="16344315" target="_blank">16344315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25519749">
<a name="25519749"></a>Yeung DT, Osborn MP, White DL, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. <i>Blood</i>. 2015;125(6):915-923.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/25519749/pubmed" id="25519749" target="_blank">25519749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20177019">
<a name="20177019"></a>Yoo C, Ryu MH, Kang BW, et al. Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib. <i>J Clin Oncol</i>. 2010;28(9):1554-1559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/20177019/pubmed" id="20177019" target="_blank">20177019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770225">
<a name="31770225"></a>Yu L, Huang X, Gale RP, Wang H, Jiang Q. Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Medicine (Baltimore)</i>. 2019;98(48):e18079. doi:10.1097/MD.0000000000018079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/imatinib-drug-information/abstract-text/31770225/pubmed" id="31770225" target="_blank">31770225</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8961 Version 475.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
